All In Biotech

Drug Trial Radar · NCT07923214

A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

A Phase I, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CG-7321 as Monotherapy or in Combination Therapy in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Jul 2, 2024

Primary completion

Apr 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CG-7321 capsules as monotherapy or in combination with fulvestrant or letrozole in subjects with advanced solid tumors. The study consists of: * Part Ia (Monotherapy): Dose escalation (accelerated titration followed by 3+3 design) from 2mg to 50mg twice daily (BID), plus dose expansion cohorts in advanced solid tumors including HR+/HER2- breast cancer, ovarian cancer, gastric cancer, and other tumor types. * Part Ib (Combination Therapy): Dose escalation of CG-7321 combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer.

Conditions

  • Advanced Solid Tumors
  • Breast Cancer
  • Ovarian Cancer
  • Gastric Cancer
  • Other Solid Tumors

Interventions

  • CG-7321Drug

    Novel oral cyclin-dependent kinase (CDK) inhibitor. Ia dose levels: 2mg, 6mg, 12mg, 20mg, 30mg, 40mg, 50mg BID. Ib dose levels: 30mg, 40mg, 50mg BID. 28-day cycle.

  • FulvestrantDrug

    Selective estrogen receptor degrader (SERD). 500mg IM on Cycle 1 Day 1 and Day 15, then Day 1 of each subsequent cycle.

  • LetrozoleDrug

    Aromatase inhibitor. 2.5mg orally once daily, continuous dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicities (DLTs)Time frame: DLT observation period [approximately 28 days]
  2. Maximum Tolerated Dose (MTD)Time frame: End of dose escalation phase [approximately 6-12 months]
  3. Recommended Phase 2 Dose (RP2D)Time frame: End of dose escalation phase [approximately 6-12 months]
  4. Adverse Events (AEs) and SAEsTime frame: From first dose to 30 days after last dose [up to approximately 2 years]

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.